Drugs / Natural Killer Cell Therapy
Trials 9
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-11-07 | Coeptis Therapeutics | Results Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development coeptis.com ↗
This is the first known study to demonstrate the safety of adoptive immunotherapy with allogeneic, off-the-shelf NK cells in patients with active COVID-19, especially those at high risk for disease progression. |
| 2024-05-20 | NKGen Biotech, Inc. | Results NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease nkgenbiotech.com ↗
SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events. |
| 2023-09-14 | Coeptis Therapeutics | Results Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection coeptis.com ↗
DVX201 was tolerated at all dosing levels. |
| 2022-02-15 | Celularity Incorporated | Regulatory Celularity Receives Orphan Drug Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers celularity.com ↗
Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational natural killer (NK) cell therapy, CYNK-101, for treatment of gastric/gastroesophageal junction cancer. |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Natural Killer Cell Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01729091 ↗ |
| Action | Deplete | “Giving third-party natural killer cells in combination with mogamulizumab may kill more cancer cells.” NCT04848064 ↗ |
| Modality | Cell therapy | “donor natural killer cell transplant” NCT00450983 ↗ |
| Route | Intravenous | “Given IV” NCT00789776 ↗ |